Lannett Acquires Adderall XR
The addition of generic Adderall to the Lannett portfolio is a major step towards making the medication more accessible to a wider range of consumers. The company plans to develop and market the generic version of Adderall XR. The acquisition will provide the company with marketing, sales, and distribution support for the drug. It will also provide the brand-name drug with an exclusive U.S. distributor. The new drug will be available on the market in early 2019.
The Lannett Company, Inc., has announced a partnership with SunGen Pharma and Elite Pharmaceuticals to distribute generic Adderall XR. Its products are used to treat narcolepsy and ADHD. IQVIA estimates its market value at $1.3 billion for the 12 months ending January 2020. The actual market value is likely to be lower. This deal will open the doors for new opportunities for the company.
The Lannett Company, Inc. is a drugmaker that develops, manufactures, packages, and distributes generic drugs. The generic versions of Adderall are approved for the treatment of narcolepsy and ADHD. This deal will ensure that the drug is available to more patients and will cost less. The Lannett Company’s product has an estimated market value of $361 million for the year ending January 2020.
Lannett Co. Inc. shares are up 3.1% in premarket trading after the drugmaker announced an agreement to sell generic Adderall. The drug is used to treat attention deficit hyperactivity disorder, narcolepsy, and sleep disorders. Its agreement with Lannett will allow the company to offer the generic version of Adderall while also providing sales support. The pharmaceutical has a market value of $361 million, according to IQVIA.
In premarket trading, shares of Lannett Co. Inc. rose 3.1%. The company has entered a deal with Elite Pharmaceuticals and SunGen Pharma to distribute generic versions of Adderall. The generics will compete directly with Adderall, and the generic versions will be cheaper than the brand. It is expected that consumers will choose the generic over the brand-name product. Aside from offering generic, Lannett will continue to produce the brand-name drug.
The generic product is more affordable than Adderall. The Lannett Company, Inc. plans to make the generic Adderall XR as a generic and will receive a percentage of the profits. The new drug is a generic form of the original drug. It has a market value of $1.3 billion for the 12 months ending January 2020. The actual value is expected to be lower. This means that generic Adderall is more accessible to a wider range of consumers.
The generic drug is the same as the brand name, but may be slightly different. However, the two differ in the amount of absorbable drug, but the FDA has determined that this difference is acceptable. Nonetheless, it is important to note that the generic drug may differ from the brand name. It is also important to note that some generics are not as effective as the brand name. The FDA has approved the additional drug in the United States, and it can be taken by people with attention-deficit disorder.
Bobby Pruett joined BestNootropics.org in 2021. As a freelance journalist, Tim has written stories for publications such as BuzzFeed and the Huffington Post. He moved to Boston in 2019, and currently covers the health stories at BestNootropics.org.